Amundi Asset Management US’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | $790M | Buy |
4,226,022
+140,830
| +3% | +$27.5M | 0.6% | 30 |
|
|
2020
Q4 | $690M | Sell |
4,085,192
-272,530
| -6% | -$40.7M | 0.59% | 31 |
|
|
2020
Q3 | $645M | Buy |
4,357,722
+161,244
| +4% | +$25M | 0.68% | 25 |
|
|
2020
Q2 | $689M | Buy |
4,196,478
+138,153
| +3% | +$21.2M | 0.82% | 20 |
|
|
2020
Q1 | $563M | Sell |
4,058,325
-847,666
| -17% | -$116M | 0.98% | 18 |
|
|
2019
Q4 | $645M | Buy |
4,905,991
+784,824
| +19% | +$91M | 0.76% | 21 |
|
|
2019
Q3 | $461M | Sell |
4,121,167
-1,300,939
| -24% | -$145M | 0.69% | 21 |
|
|
2019
Q2 | $601M | Buy |
5,422,106
+632,573
| +13% | +$74.5M | 0.49% | 57 |
|
|
2019
Q1 | $621M | Sell |
4,789,533
-1,223,289
| -20% | -$149M | 0.87% | 15 |
|
|
2018
Q4 | $696K | Buy |
6,012,822
+3,747,482
| +165% | +$419M | 0.64% | 17 |
|
|
2018
Q3 | $243M | Buy |
2,265,340
+952,382
| +73% | +$95.2M | 0.32% | 77 |
|
|
2018
Q2 | $112M | Buy |
1,312,958
+290,990
| +28% | +$23.9M | 0.16% | 142 |
|
|
2018
Q1 | $79.1M | Sell |
1,021,968
-810,658
| -44% | -$65.3M | 0.13% | 177 |
|
|
2017
Q4 | $155M | Buy |
1,832,626
+963,776
| +111% | +$82M | 0.24% | 110 |
|
|
2017
Q3 | $74.3M | Sell |
868,850
-68,800
| -7% | -$5.64M | 0.24% | 99 |
|
|
2017
Q2 | $77.2M | Sell |
937,650
-368,360
| -28% | -$30.1M | 0.25% | 95 |
|
|
2017
Q1 | $110M | Sell |
1,306,010
-68,155
| -5% | -$5.46M | 0.37% | 71 |
|
|
2016
Q4 | $101M | Buy |
1,374,165
+615,048
| +81% | +$45.8M | 0.36% | 70 |
|
|
2016
Q3 | $60.9M | Sell |
759,117
-42,330
| -5% | -$3.39M | 0.22% | 96 |
|
|
2016
Q2 | $63.1M | Sell |
801,447
-1,982
| -0.2% | -$149K | 0.23% | 101 |
|
|
2016
Q1 | $57.9M | Buy |
803,429
+57,238
| +8% | +$4.33M | 0.21% | 104 |
|
|
2015
Q4 | $62.9M | Sell |
746,191
-107,072
| -13% | -$8.89M | 0.24% | 107 |
|
|
2015
Q3 | $71.4M | Sell |
853,263
-303,843
| -26% | -$25.7M | 0.29% | 93 |
|
|
2015
Q2 | $96.6M | Buy |
1,157,106
+329,532
| +40% | +$25.1M | 0.35% | 84 |
|
|
2015
Q1 | $60.1M | Sell |
827,574
-18,091
| -2% | -$1.29M | 0.22% | 120 |
|
|
2014
Q4 | $58.3M | Sell |
845,665
-54,892
| -6% | -$3.71M | 0.21% | 129 |
|
|
2014
Q3 | $58.4M | Buy |
900,557
+574
| +0.1% | +$36.3K | 0.22% | 131 |
|
|
2014
Q2 | $56M | Buy |
899,983
+30,176
| +3% | +$1.8M | 0.21% | 131 |
|
|
2014
Q1 | $51.2M | Sell |
869,807
-2,191
| -0.3% | -$122K | 0.2% | 141 |
|
|
2013
Q4 | $44.5M | Sell |
871,998
-1,548
| -0.2% | -$77.5K | 0.17% | 157 |
|
|
2013
Q3 | $44M | Sell |
873,546
-10,206
| -1% | -$534K | 0.18% | 153 |
|
|
2013
Q2 | $43.4M | Buy |
+883,752
| New | +$48.1M | 0.18% | 155 |
|
Other funds holding LLY
Amundi Asset Management US's LLY Position: Q1 2021 in Review
Amundi Asset Management US increased its Eli Lilly (LLY) stake by 3.4% in Q1 2021, buying an estimated $27.5M and bringing the position to 4,226,022 shares worth $790M. The position accounts for 0.6% of the portfolio, ranked #30.
Amundi Asset Management US first reported a position in LLY in Q2 2013 and has held it in 32 quarters since. 1,949 funds tracked by Wall St. Rank hold LLY as of Q1 2021.
- Amundi Asset Management US held 4,226,022 shares of Eli Lilly worth $790M as of Q1 2021.
- Amundi Asset Management US bought 140,830 Eli Lilly shares in Q1 2021, an estimated $27.5M.
- Eli Lilly made up 0.6% of Amundi Asset Management US's portfolio in Q1 2021, its #30 holding.
- Amundi Asset Management US first reported a position in Eli Lilly in Q2 2013 and has held it in 32 quarters since.
- 1,949 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2021.
Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.